This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Ellenbogen, K. A. Articles by Klein, H. U. Search for Related Content PubMed PubMed Citation Articles by Ellenbogen, K. A. Articles by Klein, H. U.

Why Should We Care About CARE-HF?

Kenneth A. Ellenbogen, MD, FACC^_*,_*, Mark A. Wood, MD, FACC^_* and Helmut U. Klein, MD, FACC

^_* Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia
Division of Cardiology, University Hospital, Magdeburg, Germany

View larger version (12K): [in a new window]   Figure 1 Comparison of percentage of mortality attributable to sudden cardiac death in Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial and in Cardiac Resynchronization-Heart Failure (CARE-HF) study. Open bars = the COMPANION trial; solid bars = the CARE-HF study. CRT-D = cardiac resynchronization therapy pacemaker plus back-up defibrillation (implantable cardiac defibrillator); CRT-P = cardiac resynchronization therapy pacemaker.

View larger version (31K): [in a new window]   Figure 2 Add-on therapy in heart failure. Each added therapy incrementally decreases mortality when added on top of previous therapy. See text for explanation and references. ACE-Inh = acetylcholinesterase inhibitor; other abbreviations as in Figure 1.